Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Allergan (AGN) stocks

Learn how to buy Allergan stock in 5 easy steps.

Allergan is a drug manufacturers-general business based in the US. Allergan stocks (AGN.US) are listed on the NYSE and all prices are listed in US Dollars. Allergan employs 17,400 staff and has a trailing 12-month revenue of around $16.1 billion.

How to buy Allergan stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – AGN. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Promoted for Beginners


National Bank Direct Brokerage

  • Commission-free trading
  • Several account types available
  • Access to array of research tools

Promoted for Low Fees

CIBC Investor's Edge

  • Easy to use platform
  • Low fees
  • Student and young investor discounts

Best for Lowest Commissions

Finder Award

Interactive Brokers

  • Access to international stock exchanges
  • Low margin rates
  • Powerful research tools

Allergan stock price (NYSE:AGN)

Use our graph to track the performance of AGN stocks over time.

Allergan shares at a glance

Information last updated 2020-06-08.
52-week range$0.00 - $0.00
50-day moving average $188.84
200-day moving average $187.66
Wall St. target price$188.33
PE ratio N/A
Dividend yield $2.96 (1.53%)
Earnings per share (TTM) $-25.50

Buy Allergan stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 5 of 5
Name Product Finder Rating Available Asset Types Stock Trading Fee Account Fee Signup Offer Table description
National Bank Direct Brokerage
Finder Rating:
4.2 / 5
Stocks, Bonds, Options, Mutual Funds, GICs
$0 if conditions met, or $100
Get $0 commission on all transactions with promo code: finder
CIBC Investor's Edge
Finder Rating:
3.8 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs
$0 if conditions met, or $100
An easy-to-use platform with access to a variety of tools to help you trade with confidence.
Interactive Brokers
Finder Rating:
4.3 / 5
Stocks, Bonds, Options, ETFs, Currencies, Futures
min $1.00, max 0.5%
Winner for Best Overall Broker in the Finder Stock Trading Platform Awards.
Finder Rating:
4.3 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95 - $9.95
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio to take out some of the guesswork.
Qtrade Direct Investing
Finder Rating:
3.7 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Get up to $150 sign-up bonus. Use promo code BONUS150. Conditions apply. Ends June 30, 2023.
Low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options.

Is it a good time to buy Allergan stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Allergan stock undervalued or overvalued?

Valuing Allergan stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Allergan's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Allergan financials

Revenue TTM $16.1 billion
Operating margin TTM 6.85%
Gross profit TTM $13.7 billion
Return on assets TTM 0.74%
Return on equity TTM -4.15%
Profit margin -15.44%
Book value $175.91
Market capitalisation $63.7 billion

TTM: trailing 12 months

Allergan's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Allergan.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Allergan's total ESG risk score

Total ESG risk: 39.22

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Allergan's overall score of 39.22 (as at 01/01/2019) is pretty weak – landing it in it in the 68th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Allergan is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Allergan's environmental score

Environmental score: 5.79/100

Allergan's environmental score of 5.79 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Allergan is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Allergan's social score

Social score: 24.75/100

Allergan's social score of 24.75 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Allergan is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Allergan's governance score

Governance score: 16.68/100

Allergan's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Allergan is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Allergan's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Allergan scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Allergan hasn't always managed to keep its nose clean.

Allergan share dividends

We're not expecting Allergan to pay a dividend over the next 12 months.

Have Allergan's shares ever split?

Allergan's shares were split on a 2:1 basis on 30 October 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Allergan shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Allergan shares which in turn could have impacted Allergan's share price.

Allergan share price volatility

Over the last 12 months, Allergan's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

AGN.US volatility(beta: 1.2)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Allergan's is 1.1992. This would suggest that Allergan's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Allergan overview

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, central nervous system, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; In addition, it develops medical and cosmetic treatments; treatments for neurodegenerative disorders; and inflammatory and fibrotic diseases. It has a collaboration, option, and license agreement with Lyndra, Inc. to develop orally administered products for the treatment of Alzheimer's disease; strategic alliance and option agreement with Editas Medicine, Inc. ; and Allergan plc also has licensing agreements with Assembly Biosciences, Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site